Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU

Abstract

First-line treatment with dasatinib 100 mg once daily was associated with better and faster responses than imatinib 400 mg once daily in patients with newly diagnosed chronic-phase CML, according to the results of the ongoing randomized, open-label, multinational, phase III Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients (DASISION) trial [6], At 12 months, the confirmed com- plete cytogenetic response (cCCyR) rate (primary end- point), the complete cytogenetic response (CCyR) rate, and the major molecular response (MMR) rate were higher with dasatinib than with imatinib (Table 2) [6], After 24 months [7] and 3 years [8] of follow-up, the MMR rate remained higher in dasatinib than in imatinib recipients (Table 2).